Age and Response to Flu Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

February 9, 2020

Study Completion Date

April 20, 2020

Conditions
InfluenzaInfluenza Immunisation
Interventions
BIOLOGICAL

Influenza Virus Quadrivalent Inactivated Vaccine

A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.

BIOLOGICAL

Influenza Virus Quadrivalent Inactivated Vaccine

A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.

Trial Locations (2)

14621-3001

Rochester General Hospital - Infectious Disease Unit, Rochester

14642-0001

University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03328325 - Age and Response to Flu Vaccines | Biotech Hunter | Biotech Hunter